The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children

The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children

<h4>Objective</h4> <p>We aimed to characterise the effects of CYP2B6 polymorphisms, diurnal variation, and demographic factors on nevirapine pharmacokinetics in African children.</p> <h4>Methods</h4> <p>Nonlinear mixed-effects modelling conducted in NONMEM...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Bienczak, A, Cook, A, Wiesner, L, Mulenga, V, Kityo, C, Kekitiinwa, A, Walker, A, Owen, A, Gibb, D, Burger, D, McIlleron, H, Denti, P
Μορφή:	Journal article
Έκδοση:	Oxford University Press 2016

Παρόμοια τεκμήρια

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets
ανά: Bienczak, A, κ.ά.
Έκδοση: (2017)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
ανά: Bienczak, A, κ.ά.
Έκδοση: (2016)

Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
ανά: Oudijk, J, κ.ά.
Έκδοση: (2012)

Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children.
ανά: Bienczak, A, κ.ά.
Έκδοση: (2016)

Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial
ανά: Schomaker, M, κ.ά.
Έκδοση: (2024)

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
ανά: L'homme, R, κ.ά.
Έκδοση: (2008)

Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.
ανά: Fillekes, Q, κ.ά.
Έκδοση: (2012)

Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
ανά: Fillekes, Q, κ.ά.
Έκδοση: (2013)

Differential impact of nevirapine on artemether-lumefantrine pharmacokinetics in individuals stratified by CYP2B6 c.516G>T genotypes
ανά: Abdullahi, ST, κ.ά.
Έκδοση: (2020)

Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
ανά: Burger, D, κ.ά.
Έκδοση: (2010)

Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
ανά: Mulenga, V, κ.ά.
Έκδοση: (2010)

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
ανά: Kikaire, B, κ.ά.
Έκδοση: (2007)

Pharmacokinetics of antiretroviral drugs in infancy
ανά: Helen McIlleron, κ.ά.
Έκδοση: (2009-12-01)

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
ανά: Mulenga, V, κ.ά.
Έκδοση: (2016)

Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
ανά: Fillekes, Q, κ.ά.
Έκδοση: (2013)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
ανά: Kekitiinwa, A, κ.ά.
Έκδοση: (2017)

Virologic response to first-line efavirenz- or nevirapine-based anti-retroviral therapy in HIV-infected African children
ανά: Kekitiinwa, A, κ.ά.
Έκδοση: (2017)

Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.
ανά: Muro, E, κ.ά.
Έκδοση: (2012)

Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
ανά: Ellis, J, κ.ά.
Έκδοση: (2007)

Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
ανά: Gupta, R, κ.ά.
Έκδοση: (2010)

Getting drug doses right in children with tuberculosis (TB)
ανά: H. McIlleron
Έκδοση: (2014-04-01)

Improved adherence to antiretroviral therapy observed among HIV-infected children whose caregivers had positive beliefs in medicine in Sub-Saharan Africa
ανά: Abongomera, G, κ.ά.
Έκδοση: (2016)

The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes
ανά: Monkgomotsi J. Maseng, BSc, κ.ά.
Έκδοση: (2022-04-01)

The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
ανά: Musiime, V, κ.ά.
Έκδοση: (2014)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
ανά: Munderi, P, κ.ά.
Έκδοση: (2010)

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.
ανά: Pollock, L, κ.ά.
Έκδοση: (2009)

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
ανά: Kasirye, P, κ.ά.
Έκδοση: (2012)

Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
ανά: Liusheng Huang, κ.ά.
Έκδοση: (2017-01-01)

Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
ανά: Ndembi, N, κ.ά.
Έκδοση: (2010)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis [version 3; peer review: 1 approved, 2 approved with reservations]
ανά: Helen McIlleron, κ.ά.
Έκδοση: (2024-03-01)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis [version 2; peer review: 1 approved, 2 approved with reservations]
ανά: Helen McIlleron, κ.ά.
Έκδοση: (2022-11-01)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
ανά: Byakika-Kibwika, P, κ.ά.
Έκδοση: (2012)

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
ανά: Musiime, V, κ.ά.
Έκδοση: (2010)

A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis
ανά: Roeland E. Wasmann, κ.ά.
Έκδοση: (2023-04-01)

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana
ανά: Maseng MJ, κ.ά.
Έκδοση: (2021-03-01)

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
ανά: Musoke, P, κ.ά.
Έκδοση: (2015)

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]
ανά: Maseng MJ, κ.ά.
Έκδοση: (2021-03-01)

Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?
ανά: Fred Stephen Sarfo, κ.ά.
Έκδοση: (2014-01-01)

Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis
ανά: Jing Ling, κ.ά.
Έκδοση: (2024-08-01)

Combined antiretroviral therapy with nevirapine of HIV-infected adults
ανά: A V Kravchenko
Έκδοση: (2004-11-01)